A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...

Semaglutide is linked to a reduced risk for Alzheimer’s disease-related dementia in patients with diabetes vs other antidiabetic drugs, a new study suggests.

Among those who adhered to treatment, the high-dose group achieved an average weight loss of 20.7%, compared to 17.5% with the lower dose and 2.4% in the placebo group.

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary ...

Adults with type 2 diabetes and chronic kidney disease have a lower risk for adverse renal outcomes with semaglutide, ...

In a study looking at semaglutide, those who took a weekly dose of 2.4 mg for weight loss only — not for those with diabetes — lost an average body weight of 14.9% compared to the 2.4% in the ...

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar ...

A new study involving nearly 1.7 million patients suggests that semaglutide — a drug that mimics a gut hormone to lower blood sugar and aid weight loss — could significantly cut dementia risk in older ...

For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average.

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a serious form of fatty liver disease, a new study has found.